Breaking News Instant updates and real-time market news.

AMPE

Ampio

$0.44 /

-0.0073 (-1.63%)

06:40
03/24/20
03/24
06:40
03/24/20
06:40

Ampio prepares expanded access FDA protocol to study Ampion in ARDS

Ampio announced that it is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 induced Acute Respiratory Distress Syndrome, or ARDS, an immediately life-threatening condition. Ampio's Scientific Advisory Board, or SAB, members determined after a review of the published articles on the properties of Ampion, that nebulized Ampion may be suitable to treat another inflammatory indication. Specifically, ARDS, one of the most dreaded complications of COVID-19 is associated with widespread inflammation in the lungs. The underlying mechanism of ARDS involves diffuse injury to cells which form the barrier of the microscopic air sacs of the lung, surfactant dysfunction, and activation of the immune system. The fluid accumulation in the lungs associated with ARDS is partially explained by vascular leakage due to inflammation. Ampion is an aqueous solution that may be delivered through nebulization and may be suitable for suppressing inflammation in the lungs. Ampion is a human blood derived composition, currently approved for clinical use by the FDA, as an anti-inflammatory, immunomodulating drug. The novel mode of action of Ampion involves multiple biochemical pathways associated with resolving inflammation1 which make it a potential therapy for ARDS. An important aspect of ARDS, triggered by COVID-19, is an initial release of chemical signals and other inflammatory mediators secreted by lung epithelial and endothelial cells. Neutrophils and some T-lymphocytes migrate into the inflamed lung tissue and contribute to the amplification/deterioration of ARDS. A decrease in the production of lipid mediators of inflammation may impair the resolution of inflammation associated with ARDS. Ampion was reported to up regulate the production of these healing lipid mediators' prostaglandins in-vitro. In addition, multiple inflammatory signals have been reported to be attenuated by Ampion, including a decrease in vascular permeability. More than 1,000 patients with another inflammatory disease, osteoarthristis, have received Ampion without any serious drug related adverse events. A subset of these patients were given Ampion multiple times over the course of a year, and no serious drug related adverse events were observed. Ampion is formulated as a sterile liquid and is easily administered as a nebulized liquid form. If Ampion is found to be an efficacious treatment for COVID-19 induced ARDS, the company's in-house manufacturing facility may allow the product to be produced quickly and in significant quantities.The anticipated aim of a preliminary protocol for FDA review would be to evaluate patients with moderate to severe ARDS, triggered by COVID-19, for reduced ventilator time; reduction in mortality and improvements in oxygenation parameters compared to non-Ampion treated patients.

AMPE Ampio
$0.44 /

-0.0073 (-1.63%)

12/18/19 Roth Capital
Ampio initiated with a Buy at Roth Capital

TODAY'S FREE FLY STORIES

Hot Stocks
Quarterhill subsidiary enters license agreement with UMC regarding patents » 06:40
03/31/20
03/31
06:40
03/31/20
06:40
QTRH

Quarterhill

$0.00 /

+ (+0.00%)

Wi-LAN, a Quarterhill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Downgrade
Teladoc downgraded to Hold from Buy at Berenberg » 06:40
03/31/20
03/31
06:40
03/31/20
06:40
TDOC

Teladoc

$163.45 /

-1.11 (-0.67%)

Berenberg analyst Ravi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Insulet downgraded to Hold from Buy at Berenberg » 06:39
03/31/20
03/31
06:39
03/31/20
06:39
PODD

Insulet

$174.76 /

-0.99 (-0.56%)

Berenberg analyst Ravi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Cheesecake Factory upgraded to Buy after 60% selloff at Gordon Haskett » 06:39
03/31/20
03/31
06:39
03/31/20
06:39
CAKE

Cheesecake Factory

$16.51 /

+0.3 (+1.85%)

Gordon Haskett analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AdvanSix provides update on its business » 06:38
03/31/20
03/31
06:38
03/31/20
06:38
ASIX

AdvanSix

$8.55 /

-0.41 (-4.58%)

AdvanSix provided an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Eli Lilly announces global licensing, research collaboration with Sitryx » 06:38
03/31/20
03/31
06:38
03/31/20
06:38
LLY

Eli Lilly

$138.39 /

+4.36 (+3.25%)

Eli Lilly announced an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
BiomX: Phase 1 study of BX001 met primary endpoint » 06:37
03/31/20
03/31
06:37
03/31/20
06:37
PHGE

BiomX

$6.90 /

+ (+0.00%)

BiomX announced positive…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Tesla price target lowered to $840 from $1,060 at JMP Securities » 06:37
03/31/20
03/31
06:37
03/31/20
06:37
TSLA

Tesla

$501.85 /

-12.955 (-2.52%)

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Starboard Value reports 9.3% stake in Commvault » 06:36
03/31/20
03/31
06:36
03/31/20
06:36
CVLT

Commvault

$39.15 /

+0.7 (+1.82%)

In a regulatory filing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Denbury Resources board proposes to effect reverse stock split » 06:35
03/31/20
03/31
06:35
03/31/20
06:35
DNR

Denbury Resources

$0.21 /

-0.0243 (-10.58%)

Denbury also announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
McCormick withdraws FY20 financial outlook due to impacts of COVID-19 » 06:35
03/31/20
03/31
06:35
03/31/20
06:35
MKC

McCormick

$143.00 /

+10.75 (+8.13%)

McCormick previously…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Midatech Pharma promotes CFO Stephen Stamp to CEO » 06:34
03/31/20
03/31
06:34
03/31/20
06:34
MTP

Midatech Pharma

$1.96 /

+0.27 (+15.98%)

Craig Cook is stepping…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Denbury Resources withdraws FY20 guidance, cuts FY20 CapEx view by 44% » 06:33
03/31/20
03/31
06:33
03/31/20
06:33
DNR

Denbury Resources

$0.21 /

-0.0243 (-10.58%)

The company has reduced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
McCormick reports Q1 adj. EPS $1.08, consensus $1.03 » 06:33
03/31/20
03/31
06:33
03/31/20
06:33
MKC

McCormick

$143.00 /

+10.75 (+8.13%)

Reports Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Midatech Pharma announces scale down measures including workforce reduction » 06:33
03/31/20
03/31
06:33
03/31/20
06:33
MTP

Midatech Pharma

$1.96 /

+0.27 (+15.98%)

Midatech Pharma announces…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Microsoft price target lowered to $167 from $170 at Citi » 06:32
03/31/20
03/31
06:32
03/31/20
06:32
MSFT

Microsoft

$160.31 /

+10.65 (+7.12%)

Citi analyst Walter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Treasury urges airlines to submit grant applications by Friday, WSJ reports » 06:32
03/31/20
03/31
06:32
03/31/20
06:32
ALK

Alaska Air

$28.39 /

-1.52 (-5.08%)

, LUV

Southwest

$35.09 /

-1.3 (-3.57%)

, DAL

Delta Air Lines

$28.68 /

-0.86 (-2.91%)

, JBLU

JetBlue

$8.78 /

-0.985 (-10.09%)

, UAL

United Airlines

$30.13 /

-2.67 (-8.14%)

, SAVE

Spirit Airlines

$12.41 /

-2.29 (-15.58%)

, AAL

American Airlines

$12.25 /

-1.79 (-12.75%)

The Treasury Department…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Hexo resumed with an Underperform at BofA » 06:31
03/31/20
03/31
06:31
03/31/20
06:31
HEXO

Hexo

$0.78 /

-0.3179 (-29.03%)

BofA analyst Christopher…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Sony Pictures Networks India, WWE expand partnership in India » 06:30
03/31/20
03/31
06:30
03/31/20
06:30
SNE

Sony

$60.21 /

+0.99 (+1.67%)

, WWE

WWE

$33.39 /

-0.38 (-1.13%)

Sony Pictures Networks…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Citi removes Reata from Focus List, cuts target to $254 from $328 » 06:29
03/31/20
03/31
06:29
03/31/20
06:29
RETA

Reata Pharmaceuticals

$161.72 /

+11.53 (+7.68%)

Citi analyst Yigal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Cirrus Logic double-upgraded to Buy from Underperform at BofA » 06:28
03/31/20
03/31
06:28
03/31/20
06:28
CRUS

Cirrus Logic

$64.09 /

+2.22 (+3.59%)

, AAPL

Apple

$254.79 /

+7.05 (+2.85%)

BofA analyst Adam…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Myovant Sciences, Gedeon Richter enter license agreement for relugolix » 06:28
03/31/20
03/31
06:28
03/31/20
06:28
MYOV

Myovant Sciences

$7.77 /

+0.01 (+0.13%)

Myovant Sciences and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Hexo downgraded to Hold from Buy at Desjardins » 06:28
03/31/20
03/31
06:28
03/31/20
06:28
HEXO

Hexo

$0.78 /

-0.3179 (-29.03%)

Desjardins analyst John…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Sundial Growers redefines primary objectives for FY20 » 06:28
03/31/20
03/31
06:28
03/31/20
06:28
SNDL

Sundial Growers

$0.98 /

-0.072 (-6.86%)

Sundial has made…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Samsung Display plans to close 4 LCD lines ahead of schedule, DigiTimes reports » 06:27
03/31/20
03/31
06:27
03/31/20
06:27
SSNLF

Samsung

$0.00 /

+ (+0.00%)

Samsung Display plans to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.